Reality-monitoring & Stress
Condition(s) studied
Investigational drug(s) / intervention(s)
Acute Maastricht Stress Test (MAST), active condition.: The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the active condition, participants have to switch between immersion of the hand into cold water and complex mental arithmetic operations.
Acute Maastricht Stress Test (MAST), placebo condition: The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the placebo condition, participants have to switch between immersion of the hand into tempered water and simple mental arithmetic counts.
Study summary
Reality-monitoring is a crucial cognitive process in daily life to remember the source of an information. Deficits of reality-monitoring have been shown into the continuum of schizophrenia, suggesting a preexisting alteration in population at-risk for psychosis that will be exacerbated during psychotic transition. It is admitted that stress plays a crucial role in the psychotic transition and can alter cognitive performances. However, less is known about the effects of stress on reality-monitoring, even though this process appears to be central in psychotic disorders.
The aim of this project is to investigate the effect of stress on reality-monitoring, both on behavioral and neurophysiological aspects
Eligibility
Primary outcome measure(s)
- Reality-monitoring performances — within 1 hour after the stress procedure
scores obtained at the reality-monitoring task (accuracy, range 0-100%)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre Hospitalier le Vinatier | Bron | France | Recruiting |
More Hôpital le Vinatier trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05595434 on ClinicalTrials.gov ↗ ← All trials in France